Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function
NCT ID: NCT03331432
Last Updated: 2018-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2015-10-28
2018-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Vitamin D Supplementation on SOD,IL-6 and Insulin Resistance in Type 2 Diabetes Mellitus (DM)
NCT05596383
Effects of TUDCA on Endothelial Function in Type 2 DM
NCT03462940
Taurine Supplementation on Lower Extremity Vasculopathy in Patients With Diabetes
NCT03410537
Effect of the Chromium Nicotinate on Type 2 Diabetes
NCT01368328
ADAM17 and Vascular Function in Diabetes
NCT04557228
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Taking daily placebo capsules for 4 weeks
Placebo
Taking daily placebo capsules for 4 weeks.
Tauroursodeoxycholic acid
Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks
Tauroursodeoxycholic acid
Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tauroursodeoxycholic acid
Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
Placebo
Taking daily placebo capsules for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index less then 43 kg/m2
Exclusion Criteria
* Pregnancy
* Consumption of \>14 alcoholic beverages per week
* Changes in the medication use or dose within the last 3 months
* Known cardiovascular or pulmonary disease
* Taking medication for advanced retinopathy or neuropathy
* Taking prescription anticoagulants
* Nicotine use
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Missouri-Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jaume Padilla
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaume Padilla, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Missouri-Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Missouri
Columbia, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1203573
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.